JP Morgan Chase
CBIO

JP Morgan Chase’s Crescent Biopharma CBIO Stock Holding History

JP Morgan Chase’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-360
Closed -$449K – 5844
2019
Q1 		$449K Buy
+360
New +$412K ﹤0.01% 4261
2018
Q4 		– Sell
-360
Closed -$518K – 5766
2018
Q3 		$518K Buy
+360
New +$544K ﹤0.01% 4262
2018
Q2 		– Sell
-540
Closed -$876K – 5583
2018
Q1 		$876K Sell
540
-270
-33% -$562K ﹤0.01% 3746
2017
Q4 		$1.36M Buy
+810
New +$1.07M ﹤0.01% 3557

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase's CBIO Position: Q1 2026 in Review

JP Morgan Chase increased its Crescent Biopharma (CBIO) stake by 76% in Q1 2026, buying an estimated $203K and bringing the position to 41,004 shares worth $681K. The position accounts for ﹤0.01% of the portfolio, ranked #4815.

JP Morgan Chase first reported a position in CBIO in Q4 2014 and has held it in 32 quarters since. The position peaked at $763K in Q4 2020. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • JP Morgan Chase held 41,004 shares of Crescent Biopharma worth $681K as of Q1 2026.
  • JP Morgan Chase bought 17,665 Crescent Biopharma shares in Q1 2026, an estimated $203K.
  • Crescent Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4815 holding.
  • JP Morgan Chase first reported a position in Crescent Biopharma in Q4 2014 and has held it in 32 quarters since.
  • JP Morgan Chase's Crescent Biopharma position peaked at $763K in Q4 2020.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.